DDInter1763 DDInter1327
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Satralizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) upregulates {v} (Gene) COL11A1
COL11A1 {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) downregulates {v} (Gene) LIG1
LIG1 {u} (Gene) is upregulated by {v} (Compound) Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) downregulates {v} (Gene) LIG1
LIG1 {u} (Gene) is downregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus {u} (Compound) upregulates {v} (Gene) WDR45
WDR45 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Olaparib
Temsirolimus {u} (Compound) upregulates {v} (Gene) ALDH5A1
ALDH5A1 {u} (Gene) is downregulated by {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olaparib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) downregulates LIG1 (Gene) and LIG1 (Gene) is downregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Temsirolimus (Compound) upregulates WDR45 (Gene) and WDR45 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Olaparib
Temsirolimus (Compound) upregulates ALDH5A1 (Gene) and ALDH5A1 (Gene) is downregulated by Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib